STELLA PHARMA
NEWS
September 25th, 2024
Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma
Our product Borofalan (10B) (development code: SPM-011), which we are developin……
September 10th, 2024
Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma
Stella Pharma completed the enrollment of patients for the domestic phase II do……
September 6th, 2024
Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT
Stella Pharma announces that it has signed an agreement with the National Cance……
August 30th, 2024
Paper published: Research on Combination Therapy of BNCT and Immune Checkpoint Inhibitors
The Paper “Overcoming immunotherapy resistance and inducing abscopal effects wi……
